Venture Challenge Winner SeraNovo Enters into License Agreement with Équilibre BioPharmaceuticals.
SeraNovo BV (Leiden, The Netherlands) is pleased to announce the closing of a License Agreement with Équilibre BioPharmaceuticals Corporation (New York, USA), a biopharmaceutical company engaged in the research and development of small molecules in the field of neuroscience. Under the agreement, the companies will expand their existing collaboration and jointly develop a breakthrough product.
Niall Hodgins, Chief Executive Officer of SeraNovo commented: “We are thrilled to enter into this license agreement with Équilibre and progress another poorly water soluble drug candidate into the clinic using our deep eutectic solvent formulation platform. This agreement is a great step to broaden our customer base in North America and into the neurology field. SeraNovo are looking forward to many fruitful collaborations in these important markets.”